FibroGen to Report First Quarter 2022 Financial Results
April 25, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also...
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
February 14, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
February 04, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink...
PROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS
September 03, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...